BioAge Labs (BIOA) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioAge Labs (BIOA) has outperformed Lifecore Biomedical (LFCR) over the past year, gaining 11.8% versus a loss of 4.5%. BioAge Labs is the larger company by market cap ($287.3 million vs $244.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIOA | LFCR |
|---|---|---|
| Share price | $6.26 | $6.44 |
| Market cap | $287.31M | $244.11M |
| 1-day change | -0.48% | -0.16% |
| YTD return | -52.68% | -21.27% |
| 1-year return | +11.79% | -4.45% |
| 5-year return | — | -34.35% |
| EPS (TTM) | $-2.39 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.96 | $8.98 |
| 52-week low | $5.04 | $3.63 |
| Distance from 52-week high | -75.88% | -28.29% |
| Analyst consensus | none | hold |
| Avg. price target upside | +469.17% | -2.48% |
| Average volume | 913.77K | 289.19K |
| Shares outstanding | 45.90M | 37.91M |
| Employees | 60 | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIOA has outperformed LFCR by 16.2 percentage points over the past year.
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
BIOA vs LFCR FAQ
Which is bigger, BioAge Labs or Lifecore Biomedical?
BioAge Labs (BIOA) is larger, with a market capitalization of $287.31M compared with $244.11M for Lifecore Biomedical (LFCR).
Which stock has performed better over the past year, BIOA or LFCR?
BIOA returned +11.79% over the past 12 months, compared with -4.45% for LFCR (price return, excluding dividends). Past performance does not predict future results.
Are BioAge Labs and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.